Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

CORRECTION - Veloxis Pharmaceuticals A/S Raises FY 2013 Earnings Guidance


Wednesday, 13 Nov 2013 02:00pm EST 

HEADLINE CORRECTED TO READ...Raises FY 2013 Earnings Guidance...INSTEAD OF...Lowers FY 2013 Earnings Guidance Veloxis Pharmaceuticals A/S announced that for fiscal 2013, the Company has improved their earnings guidance and now expects an operating and net loss in the range of DKK 160 million - DKK 190 million. According to I/B/E/S estimates, analysts on average are expecting the Company to report operating profit (EBIT) of negative DKK 188.50 million and net income of negative DKK 183.50 million for fiscal 2013.